Hypothesis

Aged stem cells show a loss of early-life cis‑regulatory element (cCRE) accessibility and a gain of late-life AP‑1‑bound cCREs that drive maladaptive maturation programs. We propose that the AP‑1‑mediated opening is sustained by a local depletion of histone deacetylase activity, allowing acetyl‑lysine marks to persist and keep chromatin open. Restoring HDAC3 activity specifically at these AP‑1‑opened sites will remove acetyl groups, promote nucleosome re‑compaction, and close the late‑life cCREs without affecting global chromatin states.

Mechanistic Insight

AP‑1 factors (FOS/JUN) recruit co‑activators such as p300/CBP that acetylate H3K27 at enhancers, creating a permissive environment for transcription. In young cells, HDAC3 is recruited to these same sites via repressor complexes containing NCOR/SMRT, balancing acetylation. Age‑associated decline in NCOR/SMRT expression or post‑translational modification reduces HDAC3 recruitment, tipping the balance toward acetylation and sustained openness. By tethering HDAC3 directly to AP‑1 motifs we bypass the missing endogenous recruiters and re‑establish deacetylation, which should:

• Reduce H3K27ac at late‑life cCREs
• Increase nucleosome occupancy measured by ATAC‑seq signal loss
• Diminish AP‑1 target gene expression (e.g., MMPs, IL‑6)
• Restore early‑life cCRE accessibility and stem‑cell‑identity TF binding

Testable Predictions

1. Targeted HDAC3 recruitment to AP‑1‑bound late‑life cCREs will decrease ATAC‑seq signal at those sites by ≥30% in aged hematopoietic stem cells (HSCs).
2. The same intervention will lower expression of AP‑1‑driven senescence‑associated secretory phenotype (SASP) genes by ≥2‑fold without affecting housekeeping genes.
3. Functional assays will show improved competitive repopulation capacity in transplantation experiments (≥1.5‑fold increase in donor chimerism at 16 weeks).
4. Off‑target analysis will reveal no significant changes in early‑life cCREs or in AP‑1‑independent regions, confirming specificity.

Experimental Approach

• Construct: CRISPR‑dCas9 fused to the catalytic domain of HDAC3 (dCas9‑HDAC3) guided by a pool of sgRNAs targeting the consensus AP‑1 motif (TGACTCA) enriched in late‑life cCREs from published sci‑ATAC‑seq datasets [1].
• Cell model: Primary murine HSCs isolated from 20‑month‑old mice; cultured ex vivo with cytokine support.
• Delivery: Electroporation of ribonucleoprotein (RNP) complexes containing dCas9‑HDAC3 and sgRNA pool; include a fluorescent reporter for transfection efficiency.
• Controls: (a) dCas9‑alone with same sgRNAs, (b) dCas9‑HDAC3 with non‑targeting sgRNA, (c) untreated aged HSCs.
• Readouts:
  • sci‑ATAC‑seq to quantify accessibility changes at early‑life, late‑life, and neutral cCREs.
  • CUT&RUN for H3K27ac and HDAC3 occupancy.
  • RNA‑seq to assess transcriptional shifts, focusing on AP‑1 targets and stem‑cell signatures.
  • Functional: competitive transplantation into irradiated recipients, flow‑tracing of donor‑derived leukocytes over 16 weeks.

Expected Outcomes

If the hypothesis holds, the dCas9‑HDAC3 group will show a selective loss of accessibility and H3K27ac at AP‑1‑bound late‑life cCREs, accompanied by a gain of early‑life cCRE signal. Transcriptional reprogramming will reduce SASP and restore HSC‑specific programs, translating into superior repopulation. Control groups should exhibit no significant changes, confirming that the effect depends on both HDAC3 activity and AP‑1‑directed targeting.

Potential Pitfalls and Alternatives

• Off‑target deacetylation: Use high‑fidelity dCas9 variants and perform GUIDE‑seq to map sgRNA binding; limit sgRNA number to those with highest AP‑1 motif enrichment.
• Compensatory HAT activity: Combine HDAC3 recruitment with a low dose of p300 inhibitor (e.g., A‑485) to test synergy.
• Cell toxicity: Monitor viability and apoptosis; titrate HDAC3 domain length to balance efficacy and safety.

By directly counteracting the acetylation that stabilizes AP‑1‑driven chromatin openings, this strategy addresses a mechanistic gap left by descriptive ageing epigenomics and offers a clear, falsifiable route to rejuvenate stem‑cell function.